

# Clinical trials of exenatide other doses

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 diabetes type 2

Trial	Treatments	Patients	Trials design and methods
<b>exenatide other doses vs placebo</b>			
Moretto (DOUBLONS avec drucker) , 2008 [NCT00381342] n=155/78 follow-up: 24 weeks	Exenatide 1020 g daily versus Placebo	-	Parallel groups double blind United States, Puerto Rico, Romania, Russia, India
NCT00085969 <i>unpublished</i> [NCT00085969] n=99 follow-up: 28 days	exenatide for 28 days versus placebo	subjects with type 2 diabetes mellitus	double-blind USA
Poon , 2005 [NCT00044694] n=NA follow-up: 28 days	exenatide at 2.5, 5.0, 7.5, or 10.0 microg administered b.i.d. for 28 days versus placebo	patients with type 2 diabetes	Parallel groups double-blind
<b>exenatide other doses vs placebo (add on MER+/-SU)</b>			
Fineman , 2003 n=109 follow-up: 28 days	exenatide 3 regimen (0.08 micro g/kg) for 28 days versus placebo	patients with tyep 2 diabetes treated with diet and a sulfonylurea and/or metformin	Parallel groups double-blind USA
<b>exenatide other doses vs glargine</b>			
HEELA (Davies) , 2009 n=NA follow-up:	exenatide 5C10 g bid versus insulin glargine o.d. (titrated to target fasting plasma glucose 5.6 mmol/l)	Patients (BMI>27 kg/m2) with elevated cardiovascular risk and type 2 diabetes inadequately controlled on two or three oral antidiabetes drugs	
<b>exenatide other doses vs insulin glargine (add on MET/SU)</b>			
Trial 8078 n=NA follow-up:	exenatide versus Insulin Glargine	Patients with Type 2 Diabetes Using Metformin or Sulfonylurea for Whom Insulin Is the Next Appropriate Therapy	

More details and results :

- insulin secretagogues peptides (incretins) for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q381>

- antidiabetic drugs for diabetes type 2 in patients with insufficient glycaemic control with bitherapy at <http://www.trialresultscenter.org/go-Q511>
- antidiabetic drugs for diabetes type 2 in patients inadequately controlled on monotherapy at <http://www.trialresultscenter.org/go-Q512>
- antidiabetic drugs for diabetes type 2 in patients inadequately controlled with insulin at <http://www.trialresultscenter.org/go-Q513>

## References

### Moretto (DOUBLONS avec druker), 2008:

Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2008;30:1448-60 [[18803987](#)] [10.1016/j.clinthera.2008.08.006](https://doi.org/10.1016/j.clinthera.2008.08.006)

### NCT00085969, :

unpublished

### Poon, 2005:

Poon T, Nelson P, Shen L, Mihm M, Taylor K, Fineman M, Kim D Exenatide improves glycemc control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study. Diabetes Technol Ther 2005;7:467-77 [[15929678](#)] [10.1089/dia.2005.7.467](https://doi.org/10.1089/dia.2005.7.467)

Nelson P, Poon T, Guan X, Schnabel C, Wintle M, Fineman M The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes. Diabetes Technol Ther 2007;9:317-26 [[17705687](#)] [10.1089/dia.2006.0024](https://doi.org/10.1089/dia.2006.0024)

### Fineman, 2003:

Fineman MS, Bicsak TA, Shen LZ, Taylor K, Gaines E, Varns A, Kim D, Baron AD Effect on glycemc control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 2003;26:2370-7 [[12882864](#)]

### HEELA (Davies), 2009:

Davies MJ, Donnelly R, Barnett AH, Jones S, Nicolay C, Kilcoyne A Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study. Diabetes Obes Metab 2009 Dec;11:1153-62 [[19930005](#)]

### Trial 8078, :